[{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"a6aad9f1-0518-4d3b-a71b-32706868cb46","acronym":"ADVL1521","url":"https://clinicaltrials.gov/study/NCT03190915","created_at":"2021-01-18T15:44:00.418Z","updated_at":"2024-07-02T16:35:29.990Z","phase":"Phase 2","brief_title":"Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT03190915 - ADVL1521","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation","tags":["NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/09/2018","start_date":" 09/09/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-08"},{"id":"bf75e380-cf06-45ab-9526-c6dc47a6700e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505995","created_at":"2021-01-18T21:36:19.252Z","updated_at":"2024-07-02T16:36:42.207Z","phase":"","brief_title":"Azacitidine and Homoharringtonine in JMML","source_id_and_acronym":"NCT04505995","lead_sponsor":"Fourth Military Medical University","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2020-08-10"},{"id":"d582e599-215d-4eb6-8b2c-a2836eb99b24","acronym":"","url":"https://clinicaltrials.gov/study/NCT02447666","created_at":"2021-01-18T11:43:49.376Z","updated_at":"2024-07-02T16:36:58.220Z","phase":"Phase 2","brief_title":"Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)","source_id_and_acronym":"NCT02447666","lead_sponsor":"Celgene","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/15/2015","start_date":" 09/15/2015","primary_txt":" Primary completion: 02/28/2018","primary_completion_date":" 02/28/2018","study_txt":" Completion: 05/24/2019","study_completion_date":" 05/24/2019","last_update_posted":"2019-07-11"}]